Flag of the European Union EU Clinical Trials Register Help

Clinical trials for SAFETY

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,013 result(s) found for: SAFETY. Displaying page 788 of 1,401.
    «« First « Previous 784  785  786  787  788  789  790  791  792  Next» Last»»
    EudraCT Number: 2020-005457-25 Sponsor Protocol Number: PCN-101-21 Start Date*: 2021-08-30
    Sponsor Name:Perception Neuroscience, Inc
    Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000618-32 Sponsor Protocol Number: GNC-501 Start Date*: 2022-09-29
    Sponsor Name:GENEURO SA
    Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy...
    Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10071323 Neuropsychiatric syndrome PT
    20.0 10037175 - Psychiatric disorders 10078497 Neuropsychiatric symptoms PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000484-23 Sponsor Protocol Number: NEFRTX1 Start Date*: 2020-07-09
    Sponsor Name:Vall d'Hebron Institute of Research
    Full Title: CHARACTERIZATION OF RITUXIMAB PHARMACOKINETICS IN PATIENTS WITH KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION
    Medical condition: KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-005575-40 Sponsor Protocol Number: UZB-VHH2-4 Start Date*: 2023-02-15
    Sponsor Name:UZ Brussel
    Full Title: A phase II study to evaluate the imaging potential of 68GaNOTA-Anti-MMR VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-s...
    Medical condition: Patients diagnosed with non-small cell lung cancer (NSCLC), planned for standard-of-care (SOC) surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002728-35 Sponsor Protocol Number: HUN-AVI-01 Start Date*: 2020-09-17
    Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
    Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study −
    Medical condition: Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test with mild pneumonia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001063-27 Sponsor Protocol Number: JZP385-202-01 Start Date*: 2023-07-19
    Sponsor Name:Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
    Full Title: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Seve...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000406-28 Sponsor Protocol Number: VEN-A-QUI Start Date*: 2020-09-18
    Sponsor Name:Fundación Pethema
    Full Title: A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnos...
    Medical condition: Newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003337-41 Sponsor Protocol Number: CS1003-305 Start Date*: 2021-04-15
    Sponsor Name:CStone Pharmaceuticals (Suzhou) Co., Ltd.
    Full Title: A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First...
    Medical condition: unresectable advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) PL (Trial now transitioned) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2015-005086-23 Sponsor Protocol Number: 5.0 Start Date*: 2018-06-13
    Sponsor Name:Linnéuniversitetet
    Full Title: Mekobalamin's (Vitamin B12) effect on long-term pain in women with fibromyalgi.
    Medical condition: Fibromyalgia
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002207-36 Sponsor Protocol Number: INCB54828-801 Start Date*: 2021-11-15
    Sponsor Name:INCYTE CORPORATION
    Full Title: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
    Medical condition: Male and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002316-51 Sponsor Protocol Number: 02PDE2019 Start Date*: 2020-09-25
    Sponsor Name:Celon Pharma SA
    Full Title: Phase II, Double blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A inhibitor) in Patients with an Acute Exacerbation...
    Medical condition: Acute exacerbation of schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000493-29 Sponsor Protocol Number: CA224-069 Start Date*: 2022-05-20
    Sponsor Name:BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classica...
    Medical condition: Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004718-32 Sponsor Protocol Number: NL72607.041.20 Start Date*: 2020-10-09
    Sponsor Name:UMC Utrecht
    Full Title: Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized co...
    Medical condition: Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006464-24 Sponsor Protocol Number: 20211125 Start Date*: 2022-12-14
    Sponsor Name:Rigshospitalet, Department of Anesthesiology, Juliane Marie Center
    Full Title: Intravenous MELAtonin for prevention of Postoperative Agitation and Emergence Delirium in children. The MELA-PAED trial: a randomized, double-blind, placebo-controlled clinical trial.
    Medical condition: Emergence delirium Postoperative agitation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10050233 Delirium on emergence LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003079-41 Sponsor Protocol Number: BOLD-100-001 Start Date*: 2023-01-06
    Sponsor Name:Bold Therapeutics, Inc. (Bold)
    Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours
    Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017770 Gastric carcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000101-28 Sponsor Protocol Number: AMB-051-07 Start Date*: 2022-12-08
    Sponsor Name:AmMax Bio, Inc.
    Full Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects w...
    Medical condition: Tenosynovial Giant Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084212 Pigmented villonodular synovitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002818-16 Sponsor Protocol Number: JM-010CS-OL Start Date*: 2022-12-30
    Sponsor Name:Contera Pharma A/S
    Full Title: Open-Label Extension Study of JM-010 in Parkinson’s Disease Patients With Dyskinesia
    Medical condition: Parkinson's Disease Patients with Dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001587-38 Sponsor Protocol Number: FFCD1605 Start Date*: 2017-12-21
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: A phase II study evaluating FOLFOX + panitumumab according to a "stop and go" strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line i...
    Medical condition: metastatic colorectal adenocarcinoma without a RAS mutation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000365-37 Sponsor Protocol Number: MIN-003-1806 Start Date*: 2019-06-04
    Sponsor Name:Lipopharma Therapeutics
    Full Title: A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with ...
    Medical condition: Newly diagnosed primary glioblastoma multiforme (ndGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003916-10 Sponsor Protocol Number: GR-2021-12372898 Start Date*: 2023-04-21
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease
    Medical condition: IgG4-related disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10071569 Immunoglobulin G4 related sclerosing disease LLT
    21.1 100000004859 10071569 Immunoglobulin G4 related sclerosing disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 784  785  786  787  788  789  790  791  792  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 07:29:54 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA